Selenium Nanoparticles Synergize with a KRAS Nanovaccine against Breast Cancer

Area of Science:

• Nanomedicine
• Materials Science
• Biotechnology

Background:

• Selenium (Se) is vital for human health, exhibiting anticancer properties.
• Selenium nanoparticles (SeNPs) offer lower toxicity and higher biocompatibility than other Se compounds.
• Bare SeNPs lack stability in aqueous solutions, necessitating stabilization strategies.

Purpose of the Study:

• To develop stable selenium nanoparticles (SeNPs) using various stabilizing agents.
• To evaluate the anticancer potential of these stabilized SeNPs.
• To investigate the synergistic effect of SeNPs combined with nanovaccines in a preclinical cancer model.

Main Methods:

• Synthesis and characterization of spherical SeNPs (<100 nm) stabilized with bovine serum albumin (BSA), chitosan, and other polymers.
• Assessment of SeNP stability in various media (medium, plasma, physiological pH).
• In vitro evaluation of SeNP cytotoxicity against cancer cell lines and primary human dermal fibroblasts.
• In vivo efficacy study of BSA-SeNPs combined with a nanovaccine in an EO771 breast cancer mouse model.

Main Results:

• Optimized SeNPs were spherical, <100 nm, with narrow size distribution.
• BSA-stabilized SeNPs produced under acidic conditions exhibited superior stability in various physiological conditions, maintaining sizes of ~50-60 nm.
• SeNPs demonstrated selective toxicity towards cancer cells while sparing normal fibroblasts.
• Combination therapy with BSA-SeNPs and nanovaccine significantly reduced tumor growth (three-fold decrease) in a mouse model.

Conclusions:

• BSA-stabilized SeNPs are stable and possess selective anticancer properties.
• The synergistic effect of BSA-SeNPs with nanovaccines shows significant tumor reduction, indicating potential for improved cancer immunotherapy.
• These findings support the development of SeNPs as effective anticancer agents and in combinatorial therapeutic strategies.